title: [Treatment and prognostic factors of epithelial ovarian cancer].
abstract: OBJECTIVE
  To study the treatment results and prognostic factors of epithelial ovarian carcinoma.
  
  
  METHODS
  Retrospective study of 155 cases of ovarian epithelial carcinoma admitted in our hospital since Jan. 1970 to Dec. 1992. All of these cases had postoperative pathological diagnosis and staging according to FIGO. 42 cases had second operations and 4 cases had the third. 149 cases had postoperative chemotherapies except for 6. Chemotherapies were also given to 32 cases after the second operation, while 9 for recurrence.
  
  
  RESULTS
  The 2-year, 5-year, 10-year survival rates of stage I were 92.4%, 87.0%, 70.6%; and II 91.9%, 63.6% 47.8%; III 59.9%, 38.2%, 19.2% and IV 25.0%, 25.0%, 0.0% respectively. All 6 cases without chemotherapy after surgery died within 2 years. The results indicated that the prognosis of ovarian epithelial carcinoma was related to clinical stage, cellular grade and tumor residues. The 5-year survival rates for stage I was 87.0% and III 38.2% (P < 0.001); and cell G1 95.0% and G3 11.8% (P < 0.001), while no residual tumor 97.6% and with residual tumor > 2cm 21.2% (P < 0.001) respectively.
  
  
  CONCLUSIONS
  Residual tumor of ovarian epithelial carcinoma < 2cm after primary surgery and chemotherapy right after surgery can improve survival rates.
authors.affiliation: Gynecology Oncology Center, People's Hospital of Beijing Medical University.
authors.forename: L
authors.initials: L
authors.lastname: Wei
authors.forename: H
authors.initials: H
authors.lastname: Qian
authors.forename: W
authors.initials: W
authors.lastname: Li
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D018282:Cystadenocarcinoma, Mucinous / Q000401:mortality / Q000628:therapy*; D018284:Cystadenocarcinoma, Serous / Q000401:mortality / Q000628:therapy*; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000401:mortality / Q000628:therapy*; D012086:Reoperation; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin